Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.

Summary

The purpose of the study is to assess the effect of PF-06743649 in lowering serum uric acid in subjects suffering from gout following 14 days of dosing, as well as assessing safety and tolerability.

Timeline

Start

2014-07

Primary completion

2014-12

Completion

2014-12

Outcome

Met primary endpoint

Stopped: “B7911002 was prematurely discontinued due to a safety concern that led to decision to terminate the study on 10 Nov 2014”

registry Mean Difference (Final Values) -52.550 (90% CI -56.320 to -48.780); Bayesian ANCOVA NCT02187029 ↗

registry Mean Difference (Final Values) -66.310 (90% CI -71.310 to -61.540); Bayesian ANCOVA NCT02187029 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-06743649	Unknown	—	—

Indications